{
  "source": "PA-Notification-Fasenra.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1299-7\nProgram Prior Authorization/Notification\nMedications *Fasenra® (benralizumab)\n*This program applies to the prefilled autoinjector formulation.\nP&T Approval Date 10/2019, 4/2020, 4/2021, 11/2021, 11/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nFasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal\nantibody indicated for the add-on maintenance treatment of patients with severe asthma aged 6\nyears and older, and with an eosinophilic phenotype.\nFasenra is not used for treatment of other eosinophilic conditions or for relief of acute\nbronchospasm or status asthmaticus.\n2. Coverage Criteriaa:\nA. Asthma\n1. Initial Authorization\na. Fasenra will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Patient has been established on therapy with Fasenra under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nsevere asthma\n-AND-\n(b) Documentation of positive clinical response to Fasenra therapy\n-AND-\n(c) Fasenra will be used in combination with maintenance therapy [e.g.,\nAdvair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone\nfuroate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta\n(fluticasone furoate/umeclidinium/vilanterol)].\n-AND-\n(d) Patient is not receiving Fasenra in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Nucala\n© 2024 UnitedHealthcare Services, Inc.\n1\n(mepolizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g.,\nTezspire (tezepelumab)]\n-OR-\n(2) All of the following:\n(a) Diagnosis of severe asthma\n-AND-\n(b) Fasenra will be used in combination with maintenance therapy [e.g.,\nAdvair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone\nfuroate/vilanterol), Symbicort (bu",
    "osis of severe asthma\n-AND-\n(b) Fasenra will be used in combination with maintenance therapy [e.g.,\nAdvair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone\nfuroate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta\n(fluticasone furoate/umeclidinium/vilanterol)].\n-AND-\n(c) Asthma is an eosinophilic phenotype\n-AND-\n(d) Patient is not receiving Fasenra in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Nucala\n(mepolizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Fasenra will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Fasenra therapy\n-AND-\n(2) Fasenra will be used in combination with maintenance therapy [e.g.,\nAdvair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone\nfuroate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta\n(fluticasone furoate/umeclidinium/vilanterol)].\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n2\n(3) Patient is not receiving Fasenra in combination with any of the following:\n(a) Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Nucala\n(mepolizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\n(d) Thymic stromal lymphopoietin (TSLP) inhibitor therapy [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, ",
    "programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limitations may be in place.\n• Medical Necessity may be in place.\n• The prefilled syringe is typically covered under the medical benefit. Please refer to the\nUnited Healthcare Medical Benefit Drug Policy: “Respiratory Interleukins (Cinqair®,\nFasenra®, and Nucala®)”.\n4. References:\n1. Fasenra [prescribing information]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; April\n2024.\nProgram Prior Authorization/Notification - Fasenra (benralizumab)\nChange Control\n10/2019 New program.\n4/2020 Updated program to address specific product formulations. Updated\nreferences.\n4/2021 Annual review. No changes to clinical criteria. Added limitations of\nuse. Updated references.\n11/2021 Added coverage criteria for patients established on therapy under\nUnitedHealthcare medical benefit.\n11/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote and updated references.\n7/2023 Updated required diagnosis to “severe asthma”. Added examples of\nmaintenance therapy. Added Tezspire to list of agents that should not\nbe used in combination with Fasenra. Removed bypass of eosinophilic\nphenotype requirement for patients currently dependent on maintenance\n© 2024 UnitedHealthcare Services, Inc.\n3\ntherapy with oral corticosteroids to align with label.\n7/2024 Annual review. Updated background for ages 6 years and older.\nModified criteria for existing prior authorization for under the medical\nbenefit. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}